Project Grant R43AG079739

Award Date 9/20/23
Completion Date 4/30/25
Dollars Obligated $904K
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Kentucky, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $349,333 to Rendever, Inc. to develop and test the feasibility of a new virtual reality (VR) platform tailored to support dementia caregivers. The VR-CARES initiative aims to create a virtual community where caregivers can connect, receive training, and engage in shared experiences to alleviate feelings of loneliness and stress, and improve job satisfaction. In Phase I, the project will co-develop...
The National Institute on Aging (NIA) awarded a $864,674 Project Grant under the Aging Research program (CFDA 93.866) to Lifebio Inc., a small disadvantaged business, to develop a tablet-based platform called LifeBioTalk. This Phase I SBIR project aims to build a prototype of LifeBioTalk, which will provide stimulating audiovisual content narrated by a human-like avatar to engage people with Alzheimer's disease and related dementias (AD/ADRD). The prototype will have the ability to record...
The National Institute on Aging (NIA) awarded a $490,262 Project Grant (CFDA 93.866 - Aging Research) to Plans4Care Inc. on June 15, 2025 to develop and test a digital platform called "Activities4Care". The platform aims to provide customized, evidence-based activity plans for caregivers of people living with Alzheimer's disease and related dementias. The key products to be delivered under this Fast-Track SBIR award include: A clickable prototype of the Activities4Care platform that...
This $334,788 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) aims to investigate the impact of recent revisions to the Medicare home health payment system (Patient-Driven Groupings Model or PDGM) on access, care delivery, and outcomes for community-living Medicare beneficiaries with Alzheimer's disease and related dementias (ADRD). The 2-year study, starting September 1, 2023, will leverage Medicare claims, home health assessment, and agency data to:...
Ralphvr Inc. received a $272,082 Project Grant award from the National Science Foundation Division of Industrial Innovation on August 15, 2021 to develop a digital therapeutic virtual reality tool to address social isolation and improve geriatric care for COVID-19. The award is funded through the NSF's Engineering program (CFDA #47.041), which seeks to foster innovation and excellence in engineering research and education to improve quality of life and economic strength. Specifically, the...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $129,330 to The General Hospital Corporation (Massachusetts General Hospital) to conduct research on profiling and forecasting individual progression in Alzheimer's disease and related dementias (ADRD) using machine learning. The key products and services to be delivered under this 5-year award include: Deploying a multi-modal information framework that leverages decades-long in vivo and digital...
This $1,230,000 Project Grant awarded by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) will support the development and deployment of closed-loop digital interventions through a remote clinical trials platform. The overarching goal is to leverage technology to facilitate memory and cognitive function and prevent or delay age-related cognitive decline, particularly in older adults at risk of Alzheimer's disease and related dementias. The...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $811,228 to B.A. Maze, Inc. to develop the At-Home Health Station (AHS), a plug-and-play modular system designed to simplify digital health experiences for individuals with cognitive impairment or Alzheimer's disease and related dementias (CI/ADRD). The AHS system aims to promote health function and independence through remote patient monitoring, while also providing caregivers a platform for...
The National Institute on Aging awarded a $539,635 Project Grant under the Aging Research program (CFDA 93.866) to The RAND Corporation to develop a family-based macro-simulation model examining the supply and demand of care for Alzheimer's disease and related dementias (ADRD). The project aims to simulate individual- and family-level economic and well-being outcomes based on the factors influencing ADRD caregiving, including care needs, caregiver availability, and the cost of formal care. The...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $2,373,964 will fund a 3-year study examining the use of telehealth to improve care for long-stay nursing home residents with Alzheimer's disease and related dementias (ADRD). The key objectives are to: 1) qualitatively assess how telehealth is used in nursing homes and barriers/facilitators to its adoption, 2) characterize telehealth and in-person care utilization patterns for this population...

VRSINGTOGETHER: DIGITAL THERAPEUTIC VIRTUAL REALITY TOOL TO MITIGATE THE EFFECTS OF ALZHEIMER'S DISEASE (AD) AND ALZHEIMER'S-DISEASE-RELATED DEMENTIAS (ADRD) - PROJECT SUMMARY ONE IN THREE SENIORS DIE WITH ALZHEIMER'S DISEASE (AD) OR ALZHEIMER'S DISEASE RELATED DEMENTIAS (ADRD). MORE THAN SIX MILLION AMERICANS ARE LIVING WITH AD AND BY 2050 THIS NUMBER IS PROJECTED TO RISE TO NEARLY 13 MILLION. THE ECONOMIC COSTS OF AD ARE SIGNIFICANT, WITH 355 BILLION IN NATIONAL COSTS FOR CARING FOR PEOPLE WITH AD AND ADRD. DISCONCERTINGLY, THERE IS ALSO AN ESTIMATED 256 BILLION IN CARE PROVIDED BY FAMILY MEMBERS AND OTHER UNPAID CAREGIVERS. THESE STATISTICS ILLUSTRATE THE NECESSITY FOR SCALABLE STRATEGIES AND INTERVENTIONS TO DELAY THE ONSET OF AND HALT THE PROGRESSION OF, AD AND ADRD. INDEED, A 2020 REPORT BY THE LANCET INDICATED THAT 40% OF DEMENTIA CASES COULD BE PREVENTED BY MODIFYING LIFESTYLE FACTORS; WITH A RECOMMENDATION FOR INDIVIDUALS TO MAINTAIN COGNITIVE, PHYSICAL, AND SOCIAL ACTIVITY THROUGH MIDLIFE AND BEYOND. CRUCIALLY, INTERVENTIONS SHOULD BE INITIATED AS EARLY IN THE DISEASE PROCESS AS POSSIBLE-IN THOSE WITH NORMAL COGNITION OR ONLY MILD COGNITIVE IMPAIRMENT (MCI)-AS THE EFFECTS OF LIFESTYLE FACTORS ON DEMENTIA ONSET ARE CUMULATIVE. IN FACT, THE MCI DESIGNATION ITSELF WAS DEVELOPED TO SIGNAL THAT A PATIENT IS AT HIGHER RISK FOR AD/ADRD, PROMPTING ENHANCED CARE. IMPORTANTLY, EXISTING SOLUTIONS LEVERAGING TECHNOLOGY LACK THE ABILITY TO COMBINE PHYSICAL, COGNITIVE, AND SOCIAL MODALITIES TOGETHER DUE TO THE INABILITY TO FOSTER MEANINGFUL SOCIAL CONNECTION AND CO-PRESENCE. IN-PERSON PROGRAMS CAN FOSTER MEANINGFUL SOCIAL CONNECTIONS AND CO-PRESENCE. UNFORTUNATELY, THESE SOLUTIONS ARE ONLY ACCESSIBLE TO THOSE WITH THE TIME, MONEY, AND GEOGRAPHY TO HAVE ACCESS, AND FURTHERMORE, THESE SOLUTIONS CANNOT SCALE EFFECTIVELY. TO ADDRESS THE SIGNIFICANT UNMET NEED FOR A MULTI-MODAL INTERVENTION TO DELAY THE ONSET OF AND HALT THE PROGRESSION OF AD AND ADRD, RALPHVR IS DEVELOPING VRSINGTOGETHER, A SCALABLE DIGITAL THERAPEUTIC THAT FOSTERS SOCIAL ENGAGEMENT, MENTAL ACTIVITY, AND PHYSICAL ACTIVITY WITH MUSIC, SINGING, AND LIGHT PHYSICAL ACTIVITY THROUGH RHYTHMIC ELEMENTS IN A COLLABORATIVE AND SHARED VIRTUAL SPACE. VRSINGTOGETHER IS A NETWORKED (MULTI-USER) VR APPLICATION TO BE OFFERED ON LOW-COST COMMERCIALLY AVAILABLE VR HEADSETS. RALPHVR IS APPLYING FOR THIS NIA PHASE I SBIR TO ACHIEVE THREE SPECIFIC AIMS. AIM 1: EMPLOY A FOCUS GROUP OF EXPERTS TO GENERATE CRITICAL INSIGHTS FOR RALPHVR TO DEVELOP A DESIGN DOCUMENT. AIM 2: DEVELOP THE VRSINGTOGETHER PROTOTYPE. AIM 3: INVESTIGATE THE FEASIBILITY AND USABILITY OF VRSINGTOGETHER IN PATIENTS WITH AGE-RELATED MCI (=65 YEARS OF AGE) AND THE INDIVIDUALS WHO CARE FOR THEM (=18 YEARS OF AGE). THREE LONG-TERM OBJECTIVES MUST BE MET TO BRING VRTOGETHER TO MARKET: 1) DETERMINE THE FEASIBILITY OF VRSINGTOGETHER TO MITIGATE THE EFFECTS OF AD AND ADRD, 2) DETERMINE VRSINGTOGETHER'S EFFICACY TO PROMOTE LIGHT PHYSICAL, COGNITIVE, AND SOCIAL ACTIVITY, AND 3) DETERMINE THE EFFICACY OF VRSINGTOGETHER AS AN INTERVENTION TO SLOW OR HALT THE ONSET OF AD AND ADRD. SUCCESSFULLY COMPLETING THE LONG-TERM GOALS AND AIMS WILL RESULT IN A CLINICALLY VALIDATED SCALABLE AND LOW-COST INTERVENTION TO MITIGATE THE EFFECTS OF AD AND ADRD.

Posted 9/19/23, 12:00 AM